Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three ...
60 Degrees Pharmaceuticals Inc. SXTP shares are down during Friday’s premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday. On Wednesday, the stock surged almost 48% as the ...
Signing of a Patent License Agreement with Tufts Medical Center to jointly advance the development of tafenoquine for babesiosis treatment, indicating a strategic collaboration that enhances the ...
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) ...
Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/wells-sees-potential-upside-after-glaukos-idose-repeat ...
Morning Overview on MSN
Scientists sound alarm as deadly tick disease explodes across US region
Tick-borne diseases are spreading into new parts of the United States at a pace that has caught public health officials off guard. Babesiosis, a potentially fatal parasitic infection once confined to ...
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine, marketed as ...
OFFICERS TRUE HEROES. MULTIPLE CONFIRMED CASES. AND I’M GOING TO LET THE DOCTOR HERE TAKE THIS WORD. BABESIOSIS IN MASSACHUSETTS, THAT’S A DISEASE PRIMARILY SPREAD BY DEER TICKS. SO WE TALK A LOT ...
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results